Compare PROF & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | SSSS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 233.4M |
| IPO Year | 2017 | N/A |
| Metric | PROF | SSSS |
|---|---|---|
| Price | $6.97 | $13.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $15.67 |
| AVG Volume (30 Days) | 83.4K | ★ 391.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.61% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | $42.86 |
| P/E Ratio | $4.83 | ★ $3.61 |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $4.90 |
| 52 Week High | $8.95 | $13.66 |
| Indicator | PROF | SSSS |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 67.37 |
| Support Level | $5.75 | $8.51 |
| Resistance Level | $7.07 | $13.66 |
| Average True Range (ATR) | 0.40 | 0.40 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 74.07 | 91.54 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.